CD8A and graft versus host disease: Greenberg and colleagues cloned a high affinity TCR targeting the HLA-A2 restricted tumor antigen WT-1 from healthy donors and inserted this TCR into EBV-specific donor CD8+ T cells (to minimize the GVHD risk and enhance persistence).